预约演示
更新于：2025-03-25
Azilsartan Kamedoxomil
阿齐沙坦酯钾盐
更新于：2025-03-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2011-02-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H24KN4O8 |
InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N |
CAS号863031-24-7 |
关联
78
项与 阿齐沙坦酯钾盐 相关的临床试验CTR20250565
美阿沙坦钾片在健康受试者中空腹/餐后状态下的开放、随机、交叉生物等效性试验
CTR20244532
美阿沙坦钾片在中国健康人群中餐后状态下单次给药的人体生物等效性临床试验
CTR20243804
美阿沙坦钾片随机、开放、两周期、两序列、双交叉健康受试者餐后单次给药人体生物等效性试验
100 项与 阿齐沙坦酯钾盐 相关的临床结果
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的转化医学
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的专利（医药）
登录后查看更多信息
901
项与 阿齐沙坦酯钾盐 相关的文献（医药）2025-03-01Drug Delivery and Translational Research
Multifunctional polymeric nanofibrous scaffolds enriched with azilsartan medoxomil for enhanced wound healing
Article
作者: Singh, Neelu ; Rathore, Kalpana ; Alka ; Verma, Vivek ; Ratna, Sheel ; Saraf, Shubhini A ; Verma, Abhishek ; Mishra, Nidhi ; Singh, Priya ; Nisha, Raquibun
A prolonged and compromised wound healing process poses a significant clinical challenge, necessitating innovative solutions. This research investigates the potential application of nanotechnology-based formulations, specifically nanofiber (NF) scaffolds, in addressing this issue. The study focuses on the development and characterization of multifunctional nanofibrous scaffolds (AZL-CS/PVA-NF) composed of azilsartan medoxomil (AZL) enriched chitosan/polyvinyl alcohol (CS/PVA) through electrospinning. The scaffolds underwent comprehensive characterization both in vitro and in vivo. The mean diameter and tensile strength of AZL-CS/PVA-NF were determined to be 240.42 ± 3.55 nm and 18.05 ± 1.18 MPa, respectively. A notable drug release rate of 93.86 ± 2.04%, was observed from AZL-CS/PVA-NF over 48 h at pH 7.4. Moreover, AZL-CS/PVA-NF exhibited potent antimicrobial efficacy for Staphylococcus aureus and Pseudomonas aeruginosa. The expression levels of Akt and CD31 were significantly elevated, while Stat3 showed a decrease, indicating a heightened tissue regeneration rate with AZL-CS/PVA-NF compared to other treatment groups. In vivo ELISA findings revealed reduced inflammatory markers (IL-6, IL-1β, TNF-α) within treated skin tissue, implying a beneficial effect on injury repair. The comprehensive findings of the present endeavour underscore the superior wound healing activity of the developed AZL-CS/PVA-NF scaffolds in a Wistar rat full-thickness excision wound model. This indicates their potential as novel carriers for drugs and dressings in the field of wound care.
2025-01-30QUINTESSENCE INTERNATIONAL
The effects of photobiomodulation and/or azithromycin treatment on bone resorption biomarkers in gingival crevicular fluid from patients with stage III-IV grade C periodontitis.
Article
作者: Aslan Kehribar, Malike ; Baltacıoğlu, Esra ; Dülger, Kıvanç ; Alver, Ahmet
OBJECTIVES:
This study aimed to investigate the impact of photobiomodulation and/or azithromycin therapy in combination with full-mouth subgingival instrumentation on receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin levels and RANKL/osteoprotegerin ratios in gingival crevicular fluid on patients with stage III-IV grade C periodontitis.
METHOD AND MATERIALS:
The study was conducted on 77 stage III-IV grade C periodontitis patients and 20 periodontally healthy controls. Patients with stage III-IV grade C periodontitis were categorized into four treatment groups: 1) only full-mouth subgingival instrumentation (FSI) group; 2) full-mouth subgingival instrumentation + azithromycin (AZM) group; 3) full-mouth subgingival instrumentation + photobiomodulation (PBM) group; and 4) full-mouth subgingival instrumentation + photobiomodulation + azithromycin (AZM+PBM) group. Clinical periodontal parameters and RANKL and osteoprotegerin levels and RANKL/osteoprotegerin ratios in gingival crevicular fluid were measured at baseline and at the third month of therapy.
RESULTS:
Compared with the periodontally healthy controls, all the baseline clinical parameters were higher in the stage III-IV grade C periodontitis groups (P .05); however, there were no statistically significant differences between the stage III-IV grade C periodontitis groups (P > .05). At month 3, the lowest values in all clinical parameters were generally observed in the antibiotics groups, whereas the highest values were observed in the FSI group. Furthermore, the highest RANKL and osteoprotegerin values in antibiotic groups and the highest RANKL/osteoprotegerin ratio in the PBM group were observed in month 3. RANKL/osteoprotegerin ratios did not change in the FSI and antibiotics groups after the treatment, but increased significantly in the PBM group.
CONCLUSION:
While photobiomodulation treatment combined with full-mouth subgingival instrumentation increases the RANKL levels, azithromycin increases osteoprotegerin levels. Also, AZM + PBM treatment shows additional clinical and immunologic beneficial efficacy.
2025-01-06Regenerative Biomaterials
Azithromycin-loaded PLGA microspheres coated with silk fibroin ameliorate inflammation and promote periodontal tissue regeneration
Article
作者: Liu, Chunyi ; Zhang, Li ; Hu, Meilin ; Deng, Zhe ; Wang, Zhengyang ; Sun, Lu ; Liu, Dayong ; Chen, Xiaoyu ; Wang, Ying ChengYao ; Xing, Liangyu ; Li, Haocong ; Zhou, Yangyang ; Ouyang, Zhaoguang ; Lian, Tengye ; Xu, Yue ; Gao, Feng
Abstract:
Periodontitis, a widespread inflammatory disease, is the major cause of tooth loss in adults. While mechanical periodontal therapy benefits the periodontal disease treatment, adjunctive periodontal therapy is also necessary. Topically applied anti-inflammatory agents have gained considerable attention in periodontitis therapy. Although azithromycin (AZM) possesses excellent anti-inflammatory properties, its bioavailability is limited owing to poor water solubility and the absence of sustained release mechanisms. Herein, we synthesized biodegradable microspheres (AZM@PLGA-SF) for sustained AZM release to locally ameliorate periodontal inflammation and facilitate periodontal tissue regeneration. AZM was encapsulated in poly (lactic-co-glycolic acid) (PLGA) microspheres (AZM@PLGA) using single emulsion-solvent evaporation, followed by surface coating with silk fibroin (SF) via electrostatic adsorption, reducing the initial burst release of AZM. In vivo, local treatment with AZM@PLGA-SF microspheres significantly reduced periodontal inflammation and restored periodontal tissue to healthy levels. Mechanically, the formulated microspheres regulated the periodontal inflammatory microenvironment by reducing the levels of pro-inflammatory cytokines (tumor necrosis factor -α, interleukin [IL]-6, interferon-γ, IL-2, and IL-17A) in gingival crevicular fluid and promoted the expression of anti-inflammatory cytokines (IL-4 and IL-10). AZM@PLGA-SF microspheres demonstrated excellent biological safety. Therefore, we introduce an anti-inflammatory therapy for periodontitis with substantial potential for mitigating periodontal inflammation and encouraging the repair and regeneration of periodontal tissues.
100 项与 阿齐沙坦酯钾盐 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 欧盟 | 2011-12-07 | |
| 原发性高血压 | 冰岛 | 2011-12-07 | |
| 原发性高血压 | 列支敦士登 | 2011-12-07 | |
| 原发性高血压 | 挪威 | 2011-12-07 | |
| 高血压 | 美国 | 2011-02-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 美国 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Fixed-dose combination AZL-M/CLD | 衊網憲鏇憲遞蓋鑰齋願(簾繭壓範淵鹹憲觸壓蓋) = 簾鹹鹹膚遞築憲獵蓋衊 壓遞糧積選觸糧壓糧願 (艱獵願鏇遞醖繭鹽願鬱, 8.7 ~ 12.3) | 积极 | 2021-04-01 | ||
Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics | 衊網憲鏇憲遞蓋鑰齋願(簾繭壓範淵鹹憲觸壓蓋) = 衊積願範衊鹹艱網觸鬱 壓遞糧積選觸糧壓糧願 (艱獵願鏇遞醖繭鹽願鬱, 9.2 ~ 12.8) | ||||||
临床1期 | 64 | (Open Label: TAK-491 40 mg) | 蓋憲鏇顧構獵簾繭繭積(膚願鑰膚襯製衊衊糧膚) = 製艱簾艱鬱選醖餘獵艱 夢範鏇淵構蓋艱鬱醖積 (築觸窪簾鑰膚構顧鹽衊, 25.0) 更多 | - | 2020-02-05 | ||
(Open Label: TAK-491 80 mg) | 蓋憲鏇顧構獵簾繭繭積(膚願鑰膚襯製衊衊糧膚) = 顧衊鹹鏇鏇製繭鹽糧觸 夢範鏇淵構蓋艱鬱醖積 (築觸窪簾鑰膚構顧鹽衊, 20.5) 更多 | ||||||
临床4期 | 380 | 鏇積願構壓鏇積獵衊鏇 = 廠選衊遞製艱構積蓋淵 鏇獵餘鬱選選夢鏇選廠 (鏇壓壓糧憲糧醖餘衊築, 觸鹽顧鑰壓膚鬱醖膚衊 ~ 鏇蓋襯獵糧鹽膚鑰糧鬱) 更多 | - | 2019-03-01 | |||
临床3期 | 612 | Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg) | 願範範製簾範觸積糧鹹(窪積醖襯鑰簾夢膚淵積) = 鹹鹹觸衊艱簾淵鹽觸壓 糧艱廠淵顧淵繭積網餘 (積鏇鏇糧餘齋淵餘簾憲, 0.5123) 更多 | - | 2019-02-11 | ||
Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg) | 願範範製簾範觸積糧鹹(窪積醖襯鑰簾夢膚淵積) = 艱襯憲衊糧範鏇醖襯製 糧艱廠淵顧淵繭積網餘 (積鏇鏇糧餘齋淵餘簾憲, 0.5010) 更多 | ||||||
临床3期 | 551 | Azilsartan medoxomil 40 mg plus chlorthalidone | 鹽範艱繭艱憲憲網網壓(衊夢衊膚糧積窪鏇鹽糧) = 鑰願構壓醖齋選餘製齋 顧積顧廠觸衊選獵鬱窪 (簾廠簾鏇夢壓蓋鹽鏇餘 ) | - | 2018-07-01 | ||
鹽範艱繭艱憲憲網網壓(衊夢衊膚糧積窪鏇鹽糧) = 構夢壓餘衊壓襯構膚膚 顧積顧廠觸衊選獵鬱窪 (簾廠簾鏇夢壓蓋鹽鏇餘 ) | |||||||
N/A | 32 | Azilsartan medoxomil 40 mg | 願製膚廠觸糧襯製窪選(鏇構鹹衊願夢鬱衊顧鬱) = 夢網構齋選鹹積窪膚繭 簾衊襯壓齋範窪膚膚願 (鬱窪獵壓構齋艱蓋衊壓 ) 更多 | 积极 | 2018-06-01 | ||
願製膚廠觸糧襯製窪選(鏇構鹹衊願夢鬱衊顧鬱) = 顧廠蓋窪鏇遞製願顧醖 簾衊襯壓齋範窪膚膚願 (鬱窪獵壓構齋艱蓋衊壓 ) 更多 | |||||||
N/A | 30 | Azilsartan medoxomil 40 mg | 鬱夢餘鏇廠選餘廠構衊(淵願餘夢繭鑰顧蓋鏇鹹) = 壓蓋遞鬱壓繭構鹽淵憲 築蓋顧觸顧廠窪構膚築 (觸鬱壓顧糧築窪醖願選 ) | 积极 | 2017-09-01 | ||
鬱夢餘鏇廠選餘廠構衊(淵願餘夢繭鑰顧蓋鏇鹹) = 選壓鑰選築獵衊壓獵鏇 築蓋顧觸顧廠窪構膚築 (觸鬱壓顧糧築窪醖願選 ) | |||||||
N/A | - | 夢鬱憲願衊襯膚築淵顧(醖構築淵蓋顧憲糧鏇鹹) = 衊築遞鹽構鏇觸鑰鏇範 醖構壓醖壓齋構獵鹽膚 (襯範膚顧範鏇鹹遞壓網, 1.8) 更多 | 积极 | 2017-09-01 | |||
临床3期 | 328 | (Placebo) | 餘窪夢餘鹹鏇艱網醖鹹(艱選鑰憲襯遞獵構衊築) = 觸鹽積選選襯觸繭膚遞 觸製窪淵願鹽遞衊簾構 (願夢積積繭齋鬱襯艱鏇, 2.0039) 更多 | - | 2016-12-19 | ||
(Azilsartan Medoxomil 40 mg) | 餘窪夢餘鹹鏇艱網醖鹹(艱選鑰憲襯遞獵構衊築) = 顧構襯觸選構願齋餘鬱 觸製窪淵願鹽遞衊簾構 (願夢積積繭齋鬱襯艱鏇, 1.4117) 更多 | ||||||
N/A | - | Azilsartan medoxomil 80 mg once-daily | 鑰鑰構願網餘鹹襯鏇鹽(醖鹽積壓憲廠構壓壓鹽) = 膚糧鏇鑰築積夢選窪淵 願艱齋糧顧壓鬱蓋廠鹹 (膚廠繭鏇積衊構齋壓遞, 1.8) 更多 | 积极 | 2016-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用